Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Research highlights Treatment options for myeloma bone disease have increased during the last years. Denosumab is an RANKL inhibitor that has shown its noninferiority in SRE prevention compared to zoledronic acid. Denosumab may constitute a safer option for patients with…